Telix doses first patient in TLX591-Px prostate imaging trial
Telix Pharmaceuticals has dosed the first patient in its pivotal Phase III registration study of TLX591-Px (Illuccix, Kit for the…
News
Ascletis reports positive results in Phase III denifanstat trial for acne
Repertoire and Lilly join hands on autoimmune disease therapies
Ardelyx begins patient dosing in Phase III trial for CIC
RevBio receives FDA clearance for cranial bone glue trial
FDA grants breakthrough status to Biogen’s litifilimab for CLE
QT Imaging and Olea Medical collaborate on cloud-based breast analytics
Arrowhead begins dosing in Phase I/IIa trial for hyperlipidaemia
